BACKGROUND
The clinical significance of sarcomere variants of uncertain significance (VUS) in hypertrophic cardiomyopathy (HCM) remains unclear. Despite their increasing prevalence, VUS are often regarded as clinically nonactionable.
OBJECTIVES
The authors evaluated genotype-phenotype and genotype-outcome association...
Hong-Mi Choi, S. Seo, In-Chang Hwang et al.· JACC: Asia· 0 citations
BACKGROUND
Cardiac reverse remodeling and associated clinical outcomes following angiotensin receptor-neprilysin inhibitor (ARNI) therapy in patients with heart failure (HF) with reduced ejection fraction (EF) remain unclear. We investigated differences in 1-year echocardiographic response after ARNI therapy and predic...
N. Y. Bae, S. Kwak, C. Park et al.· Journal of the American Hear...· 0 citations
LARS was an independent predictor of SCD-related events and effectively stratified risk among patients classified as low-to-intermediate risk by the HCM Risk-SCD score and adding LARS to the HCM Risk-SCD score significantly improved risk discrimination in the low-to-intermediate risk population.
S. Kwak, Younghyun Kang, Ji-Hyun Kim et al.· Journal of the American Soci...· 0 citations
The proposed LA staging framework offers mechanistic insights into how the LA adapts to progressive diastolic dysfunction in HCM and is associated with a graded risk of NOAF and may help tailor AF surveillance strategies.
Jaehyun Lim, I. Hwang, Ji-Hyun Kim et al.· Journal of the American Coll...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.